. The importance of GPIb-IX and vWF in that promotes platelet activation followed by a delayed thrombosis and hemostasis is manifested in the inherplatelet inhibition that serves to limit the size of platelet ited diseases Bernard-Soulier syndrome and von Willeaggregates. Our findings explain previous controversies and provide revisions to the current concept of cGMP signaling in platelet activation.
Results

PKG Promotes GPIb-IX-Mediated Integrin Activation in a Reconstituted
; WT). Spreading of wild-type platelets was integrin dependent since it was blocked by the integrin inhibitor, RGDS ( Figure 3A , RGDS). In contrast to wildtype mice, platelets from PKG knockout mice spread poorly on vWF, in a manner similar to RGDS-treated (D) Bleeding time tests were performed blind to genotype in litWild-type platelets were also preincubated with the PKG inhibitor termate mice (5-6 weeks old) generated from mating PKG ϩ/Ϫ mice, Rp-pCPT-cGMP (0.25 mM) for 5 min and then exposed to 0.025/ml using methods described under Experimental Procedures. Geno-␣-thrombin.
types of the tested mice were subsequently determined by PCR (E) A subthreshold dose of thrombin was added to wild-type (WT) analysis. The solid triangles represent the bleeding time of a single or PKG Ϫ/Ϫ (KO) mouse platelets followed immediately by addition mouse. The bar represents the median bleeding time of the group. of the PKG activator 8-bromo-cGMP (10 M) or buffer (control).
Note that although the variance of bleeding time was broad in both the control and PKG Ϫ/Ϫ groups (reflecting that multiple factors may influence the outcome of this in vivo test), the difference between thrombin-induced platelet activation, a low dose of PKG ϩ/ϩ and PKG Ϫ/Ϫ mice is statistically significant (p ϭ 0.017).
␣-thrombin was added to platelets from wild-type or PKG knockout mice to induce aggregation. We found that platelet aggregation was markedly reduced in PKG knockout mice compared to wild-type mice ( Figure 5D ).
The cGMP-Enhancing Drug Sildenafil Promotes Platelet Activation In Vitro Wild-type platelets treated with the PKG inhibitor RppCPT-cGMP also showed reduced platelet aggregation
The cGMP-enhancing drug sildenafil increases intracellular cGMP and activates PKG. Thus, if PKG stimulates similar to PKG knockout mice ( Figure 5D ). As previously reported (Massberg et al., 1999) , collagen-induced platelet activation, sildenafil might also be stimulatory. ., 1999) , Thus, the biphasic response of activation. Although it is known that vWF binding to platelets to cGMP elevation may be of physiological GPIb-IX activates platelets, the signaling pathways resignificance because this response would not only memain poorly defined. Thus, our finding of a PKG-dependiate rapid activation of platelets upon vascular injury dent platelet activation pathway is significant not only and formation of a primary hemostatic thrombus, but because it provides convincing evidence of a stimulawould also serve to inhibit the overgrowth of thrombus tory role for PKG in platelet activation, but also because to prevent the occlusion of blood vessels during normal it defines a novel signaling mechanism of platelet adhehemostasis ( Figure 7C ). The mechanisms for the biphasion and activation. sic effect of cGMP remain to be investigated. Our data An important platelet agonist, thrombin, requires suggest that cGMP induces an early activation of the PARs to induce platelet activation. However, at low ERK pathway that is important in platelet activation (Li et thrombin concentrations, PARs are not sufficient, and al., 2001), followed by a delayed VASP phosphorylation, a different thrombin receptor, GPIb-IX, is also required.
which is involved in platelet inhibition ( Figure 7B) . We At present, it is not clear how GPIb-IX is involved in have also found that cAMP-dependent protein kinase thrombin-induced platelet activation. One hypothesis is is important in cGMP-induced VASP phosphorylation that GPIb-IX functions as a thrombin-presenting recepand platelet inhibition (Z. Li et al., submitted). Thus, tor that enhances the interaction between PARs and one of the possible mechanisms for the transition from thrombin (Coughlin, 2000) . Alternatively, it is hypothestimulatory to inhibitory responses may involve the sized that GPIb-IX may transmit signals that synergize crosstalk between the cGMP and cAMP pathways. with PARs in promoting platelet activation (Greco et Our finding of a stimulatory role of the cGMP-PKG al., 1996). Our data suggest a possible PKG-dependent pathway in platelet activation is important not only to signaling mechanism for the synergism between GPIbthe understanding of platelet physiology, but also to the IX and PARs. It is important to note that the stimulatory pharmacology and therapeutic applications of cGMProle of cGMP manifests only when platelets are exposed enhancing drugs such as sildenafil. Our data suggest simultaneously to the agonists, ␣-thrombin, or vWF. Elethat although sildenafil by itself is not sufficient to cause vation of cGMP alone is not sufficient to activate plateplatelet aggregation, this drug enhances platelet activalets (data not shown). Thus, it appears that the cGMPtion in the presence of subthreshold concentrations of PKG pathway is not the only pathway required for thrombin or vWF, agonists that are likely to be present GPIb-IX-mediated integrin activation. In this respect, it at sites of vascular injury or atherosclerotic lesions. 
